Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul>
<li>We are initiating coverage of FibroBiologics, Inc. (FBLG) with an $11.00 valuation.</li>
<li>FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with significant unmet medical needs.</li>
<li>We anticipate that a Phase 1/2 clinical trial of CYWC628, the company's lead asset targeting diabetic foot ulcers, will be completed in Australia in 2025.</li>
</ul>


We are initiating coverage of FibroBiologics, Inc. (FBLG) with an $11.00 valuation.
FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with significant unmet medical needs.
We anticipate that a Phase 1/2 clinical trial of CYWC628, the company's lead asset targeting diabetic foot ulcers, will be completed in Australia in 2025.


FibroBiologics

FibroBiologics, Inc. - June 24, 2024